Crizotinib - Still "gold standard" for patients with pulmonary adenocarcinoma with ALK translocation?
2017
Abstract
Crizotinib is a tyrosine kinase inhibitor targeting ALK translocation. Based on Profile 1007 and Profile 1014 trial, it has become the basis of treatment for patients with ALK translocation in the first as well as the second line of treatment.
Its toxic profile is acceptable and usually well manageable. In the Czech Republic, due to the form of payment, it has been used exclusively in the second line, where we document the experience from our workplace with this drug.
Currently, other drugs (ceritinib, alectinib) have proven to be effective in patients with ALK translocations, when it is a question of choosing a treatment plan, which is discussed in more detail in the discussion.